Pathophysiology of idiopathic atrial fibrillation-prognostic and treatment implications

Current Pharmaceutical Design

Volumn 21, Issue 5, 2015, Pages 551-572

  Weijs, B ^a   Schotten, U ^a   Crijns, H ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Atrial fibrillation; Cardiovascular disease; Idiopathic; Lone; Pathophysiology

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSINOGEN; ANTICOAGULANT AGENT; ATRIAL NATRIURETIC FACTOR; CALCIUM; CONNEXIN 47; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.1; NUCLEAR PROTEIN; POTASSIUM; POTASSIUM CHANNEL KCNQ1; POTASSIUM CHANNEL KV1.5; RYANODINE RECEPTOR 2; SCAFFOLD PROTEIN; SODIUM; SODIUM CHANNEL NAV1.5; TRANSCRIPTION FACTOR GATA 4; TRANSCRIPTION FACTOR NKX2.5; TRANSCRIPTION FACTOR PITX2;

AGING; ANGER; ANTICOAGULANT THERAPY; ARTICLE; ATHEROSCLEROSIS; CARDIOMYOPATHY; CHANNELOPATHY; CONGENITAL HEART DISEASE; DIABETES MELLITUS; FAMILY HISTORY; GENE MUTATION; HEART ATRIUM CONDUCTION; HEART ATRIUM ENLARGEMENT; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; LUNG DISEASE; MYOCARDITIS; OBESITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SLEEP DISORDERED BREATHING; SMOKING; THROMBOEMBOLISM; THYROID DISEASE; TUMOR SUPPRESSOR GENE; VALVULAR HEART DISEASE; VASCULAR DISEASE; ATRIAL FIBRILLATION; ECHOCARDIOGRAPHY; GENETIC PREDISPOSITION; HEART FUNCTION TEST; PREVENTIVE HEALTH SERVICE; PROGNOSIS; RISK FACTOR; SEX DIFFERENCE;

ATRIAL FIBRILLATION; ECHOCARDIOGRAPHY; ELECTROPHYSIOLOGIC TECHNIQUES, CARDIAC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; PREVENTIVE HEALTH SERVICES; PROGNOSIS; RISK FACTORS; SEX FACTORS;

EID: 84925840288     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612820666140825150057     Document Type: Article

References (406)

1. Cushny AR, Edmunds CW. Paroxysmal irregularity of the heart and auricular fibrillation. In: Bulloch W, ed Studies in pathology Aberdeen, Scotland: Universty of Aberdeen 1906: 95-110.
2. Einthoven W. Le Telecardiogramme. Arch Int Physiol 1906; 4: 132-64.
3. Fye WB. Tracing atrial fibrillation--100 years. N Engl J Med 2006; 355: 1412-4.
4. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369-429.
5. Lip GY, Beevers DG. ABC of atrial fibrillation. History, epidemiology, and importance of atrial fibrillation. BMJ 1995; 311: 1361-3.
6. Nattel S. New ideas about atrial fibrillation 50 years on. Nature 2002; 415: 219-26.
7. Kirchhof P, Bax J, Blomstrom-Lundquist C, et al. Early and comprehensive management of atrial fibrillation: proceedings from the 2nd AFNET/EHRA consensus conference on atrial fibrillation entitled 'research perspectives in atrial fibrillation'. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 2009; 11: 860-85.
8. Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006; 114: 119-25.
9. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA : the journal of the American Medical Association 2001; 285: 2370-5.
10. Benjamin EJ, Wolf PA, D'Agostino RB, et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998; 98: 946-52.
11. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med 1987; 147: 1561-4.
12. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22: 983-8.
13. Investigators AF. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 1449-57.
14. Stewart S, Hart CL, Hole DJ, et al. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med 2002; 113: 359-64.
15. Benjamin EJ, Levy D, Vaziri SM, et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA : the journal of the American Medical Association 1994; 271: 840-4.
16. Holstenson E, Ringborg A, Lindgren P, et al. Predictors of costs related to cardiovascular disease among patients with atrial fibrillation in five European countries. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 2011; 13: 23-30.
17. Kannel WB, Wolf PA, Benjamin EJ, et al. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998; 82: 2N-9N.
18. Ringborg A, Nieuwlaat R, Lindgren P, et al. Costs of atrial fibrillation in five European countries: results from the Euro Heart Survey on atrial fibrillation. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 2008; 10: 403-11.
19. Nabauer M, Gerth A, Limbourg T, et al. The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 2009; 11: 423-34.
20. Nieuwlaat R, Capucci A, Camm AJ, et al. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2005; 26: 2422-34.
21. Conen D, Tedrow UB, Koplan BA, et al. Influence of systolic and diastolic blood pressure on the risk of incident atrial fibrillation in women. Circulation 2009; 119: 2146-52.
22. Brand FN, Abbott RD, Kannel WB, et al. Characteristics and prognosis of lone atrial fibrillation. 30-year follow-up in the Framingham Study. Jama 1985; 254: 3449-53.
23. Evans W, Swann P. Lone auricular fibrillation. Br Heart J 1954; 16: 189-94.
24. Jouven X, Desnos M, Guerot C, et al. Idiopathic atrial fibrillation as a risk factor for mortality. The Paris Prospective Study I. Eur Heart J 1999; 20: 896-9.
25. Kannel WB, Abbott RD, Savage DD, et al. Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med 1982; 306: 1018-22.
26. Kopecky SL. Idiopathic atrial fibrillation: prevalence, course, treatment, and prognosis. J Thromb Thrombolysis 1999; 7: 27-31.
27. Kopecky SL, Gersh BJ, McGoon MD, et al. The natural history of lone atrial fibrillation. A population-based study over three decades. N Engl J Med 1987; 317: 669-74.
28. Kozlowski D, Budrejko S, Lip GY, et al. Lone atrial fibrillation: what do we know? Heart 2010; 96: 498-503.
29. Levy S. Epidemiology and classification of atrial fibrillation. J Cardiovasc Electrophysiol 1998; 9: S78-82.
30. Allessie MA, Boyden PA, Camm AJ, et al. Pathophysiology and prevention of atrial fibrillation. Circulation 2001; 103: 769-77.
31. Benjamin EJ, D'Agostino RB, Belanger AJ, et al. Left atrial size and the risk of stroke and death. The Framingham Heart Study. Circulation 1995; 92: 835-41.
32. Osranek M, Bursi F, Bailey KR, et al. Left atrial volume predicts cardiovascular events in patients originally diagnosed with lone atrial fibrillation: three-decade follow-up. Eur Heart J 2005; 26: 2556-61.
33. Haissaguerre M, Jais P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998; 339: 659-66.
34. Hocini M, Haissaguerre M, Shah D, et al. Multiple sources initiating atrial fibrillation from a single pulmonary vein identified by a circumferential catheter. Pacing and clinical electrophysiology : PACE 2000; 23: 1828-31.
35. Jais P, Shah DC, Haissaguerre M, et al. Atrial fibrillation: role of arrhythmogenic foci. Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing 2000; 4 Suppl 1: 29-37.
36. Mandapati R, Skanes A, Chen J, et al. Stable microreentrant sources as a mechanism of atrial fibrillation in the isolated sheep heart. Circulation 2000; 101: 194-9.
37. Moe GK. A conceptual model of atrial fibrillation. Journal of electrocardiology 1968; 1: 145-6.
38. Moe GK, Rheinboldt WC, Abildskov JA. A Computer Model of Atrial Fibrillation. Am Heart J 1964; 67: 200-20.
39. Nattel S, Li D, Yue L. Basic mechanisms of atrial fibrillation--very new insights into very old ideas. Annual Rev Physiol 2000; 62: 51-77.
40. Schotten U, Verheule S, Kirchhof P, et al. Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. Physiological Rev 2011; 91: 265-325.
41. Shiroshita-Takeshita A, Brundel BJ, Nattel S. Atrial fibrillation: basic mechanisms, remodeling and triggers. Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing 2005; 13: 181-93.
42. Allessie MA, Bonke FI, Schopman FJ. Circus movement in rabbit atrial muscle as a mechanism of trachycardia. Circ Res 1973; 33: 54-62.
43. Lammers WJ, Allessie MA. Pathophysiology of atrial fibrillation: current aspects. Herz 1993; 18: 1-8.
44. Wijffels MC, Kirchhof CJ, Dorland R, et al. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 1995; 92: 1954-68.
45. Allessie MA, Konings K, Kirchhof CJ, et al. Electrophysiologic mechanisms of perpetuation of atrial fibrillation. Am J Cardiol 1996; 77: 10A-23A.
46. Ravelli F, Allessie M. Effects of atrial dilatation on refractory period and vulnerability to atrial fibrillation in the isolated Langendorff-perfused rabbit heart. Circulation 1997; 96: 1686-95.
47. Timmermans C, Rodriguez LM, Crijns HJ, et al. Idiopathic left bundle-branch block-shaped ventricular tachycardia may originate above the pulmonary valve. Circulation 2003; 108: 1960-7.
48. Khan IA. Atrial fibrillation: interaction between the trigger and the substrate. Int J Cardiol 2003; 87: 301-2.
49. De PR, Ho SY, Salerno-Uriarte JA, et al. Electroanatomic analysis of sinus impulse propagation in normal human atria. J Cardiovasc Electrophysiol 2002; 13: 1-10.
50. Pytkowski M, Jankowska A, Maciag A, et al. Paroxysmal atrial fibrillation is associated with increased intra-atrial conduction delay. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 2008; 10: 1415-20.
51. Stiles MK, John B, Wong CX, et al. Paroxysmal lone atrial fibrillation is associated with an abnormal atrial substrate: characterizing the "second factor". J Am Coll Cardiol 2009; 53: 1182-91.
52. Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002; 347: 1834-40.
53. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825-33.
54. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 guidelines for the management of patients with atrial fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace 2006; 8: 651-745.
55. Psaty BM, Manolio TA, Kuller LH, et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation 1997; 96: 2455-61.
56. Rosiak M, Dziuba M, Chudzik M, et al. Risk factors for atrial fibrillation: Not always severe heart disease, not always so 'lonely'. Cardiol J 2010; 17: 437-42.
57. Schnabel RB, Sullivan LM, Levy D, et al. Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study. Lancet 2009; 373: 739-45.
58. Asselbergs FW, van den Berg MP, Diercks GF, et al. C-reactive protein and microalbuminuria are associated with atrial fibrillation. International journal of cardiology 2005; 98: 73-7.
59. Auer J, Scheibner P, Mische T, et al. Subclinical hyperthyroidism as a risk factor for atrial fibrillation. Am Heart J 2001; 142: 838-42.
60. Buch P, Friberg J, Scharling H, et al. Reduced lung function and risk of atrial fibrillation in the Copenhagen City Heart Study. The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology 2003; 21: 1012-6.
61. Conen D, Tedrow UB, Cook NR, et al. Birth weight is a significant risk factor for incident atrial fibrillation. Circulation 2010; 122: 764-70.
62. Djousse L, Levy D, Benjamin EJ, et al. Long-term alcohol consumption and the risk of atrial fibrillation in the Framingham Study. Am J Cardiol 2004; 93: 710-3.
63. Eaker ED, Sullivan LM, Kelly-Hayes M, et al. Anger and hostility predict the development of atrial fibrillation in men in the Framingham Offspring Study. Circulation 2004; 109: 1267-71.
64. Gami AS, Hodge DO, Herges RM, et al. Obstructive sleep apnea, obesity, and the risk of incident atrial fibrillation. J Am Coll Cardiol 2007; 49: 565-71.
65. Heeringa J, van der Kuip DA, Hofman A, et al. Subclinical atherosclerosis and risk of atrial fibrillation: the rotterdam study. Arch Intern Med 2007; 167: 382-7.
66. Horio T, Iwashima Y, Kamide K, et al. Chronic kidney disease as an independent risk factor for new-onset atrial fibrillation in hypertensive patients. J Hypertension 2010; 28: 1738-44.
67. Mitchell GF, Vasan RS, Keyes MJ, et al. Pulse pressure and risk of new-onset atrial fibrillation. Jama 2007; 297: 709-15.
68. Mont L, Tamborero D, Elosua R, et al. Physical activity, height, and left atrial size are independent risk factors for lone atrial fibrillation in middle-aged healthy individuals. Europace 2008; 10: 15-20.
69. Weijs B, Pisters R, Nieuwlaat R, et al. Idiopathic atrial fibrillation revisited in a large longitudinal clinical cohort. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 2012; 14: 184-90.
70. Wang Z, Lu Y, Yang B. MicroRNAs and atrial fibrillation: new fundamentals. Cardiovascular Res 2011; 89: 710-21.
71. Tran NT, Larry Klein J, Paul Mounsey J, et al. Lone atrial fibrillation is associated with pectus excavatum. Heart Rhythm 2013.
72. Delmar M, Makita N. Cardiac connexins, mutations and arrhythmias. Curr Opin Cardiol 2012; 27: 236-41.
73. Allessie M, Ausma J, Schotten U. Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovascular Res 2002; 54: 230-46.
74. Boos CJ, Anderson RA, Lip GY. Is atrial fibrillation an inflammatory disorder? Eur Heart J 2006; 27: 136-49.
75. Potpara TS, Lip GY. Lone atrial fibrillation: what is known and what is to come. International journal of clinical practice 2011; 65: 446-57.
76. Roberts JD, Gollob MH. Impact of genetic discoveries on the classification of lone atrial fibrillation. J Am Coll Cardiol 2010; 55: 705-12.
77. Kourliouros A, Savelieva I, Kiotsekoglou A, et al. Current concepts in the pathogenesis of atrial fibrillation. Am Heart J 2009; 157: 243-52.
78. Sitges M, Teijeira VA, Scalise A, et al. Is there an anatomical substrate for idiopathic paroxysmal atrial fibrillation? A case-control echocardiographic study. Europace 2007; 9: 294-8.
79. Davidson E, Rotenberg Z, Weinberger I, et al. Diagnosis and characteristics of lone atrial fibrillation. Chest 1989; 95: 1048-50.
80. Fowler WM, Baldridge CW. Auricular fibrillation as the only manifestation of heart disease. Am Heart J 1930; 6: 183-91.
81. Friedlander RD, Levine SA. Auricular fibrillation and flutter without evidence of organic heart disease. N Engl J Med 1934; 211: 624.
82. Neufeld HN, Wagenvoort CA, Burchell HB, et al. Idiopathic atrial fibrillation. Am J Cardiol 1961; 8: 193-7.
83. Phillips E, Levine SA. Auricular fibrillation without other evidence of heart disease; a cause of reversible heart failure. Am J Med 1949; 7: 478-89.
84. Coumel P. Cardiac arrhythmias and the autonomic nervous system. J Cardiovasc Electrophysiol 1993; 4: 338-55.
85. Coumel P. Paroxysmal atrial fibrillation: a disorder of autonomic tone? Eur Heart J 1994; 15 Suppl A: 9-16.
86. de Vos CB, Nieuwlaat R, Crijns HJ, et al. Autonomic trigger patterns and anti-arrhythmic treatment of paroxysmal atrial fibrillation: data from the Euro Heart Survey. Eur Heart J 2008; 29: 632-9.
87. Brugada R, Tapscott T, Czernuszewicz GZ, et al. Identification of a genetic locus for familial atrial fibrillation. N Engl J Med 1997; 336: 905-11.
88. Dublin S, French B, Glazer NL, et al. Risk of new-onset atrial fibrillation in relation to body mass index. Arch Intern Med 2006; 166: 2322-8.
89. Dublin S, Glazer NL, Smith NL, et al. Diabetes mellitus, glycemic control, and risk of atrial fibrillation. Journal of general internal medicine 2010; 25: 853-8.
90. Porthan KM, Melin JH, Kupila JT, et al. Prevalence of sleep apnea syndrome in lone atrial fibrillation: a case-control study. Chest 2004; 125: 879-85.
91. Schoonderwoerd BA, Smit MD, Pen L, et al. New risk factors for atrial fibrillation: causes of 'not-so-lone atrial fibrillation'. Europace 2008.
92. Wolf L. Familial auricular fibrillation. N Engl J Med 1943; 229: 396.
93. Fox CS, Parise H, D'Agostino RB, Sr., et al. Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring. Jama 2004; 291: 2851-5.
94. Christophersen IE, Ravn LS, Budtz-Joergensen E, et al. Familial aggregation of atrial fibrillation: a study in Danish twins. Circ Arrhythm Electrophysiol 2009; 2: 378-83.
95. Ellinor PT, Yoerger DM, Ruskin JN, et al. Familial aggregation in lone atrial fibrillation. Hum Genet 2005; 118: 179-84.
96. Darbar D, Herron KJ, Ballew JD, et al. Familial atrial fibrillation is a genetically heterogeneous disorder. J Am Coll Cardiol 2003; 41: 2185-92.
97. Fatkin D, Otway R, Vandenberg JI. Genes and atrial fibrillation: a new look at an old problem. Circulation 2007; 116: 782-92.
98. Rosenberg NA, Huang L, Jewett EM, et al. Genome-wide association studies in diverse populations. Nat Rev Genet 2010; 11: 356-66.
99. Ellinor PT, MacRae CA. Ion channel mutations in AF: signal or noise? Heart Rhythm 2008; 5: 436-7.
100. Sabeh MK, MacRae CA. The genetics of atrial fibrillation. Curr Opin Cardiol 2010; 25: 186-91.
101. Chen SA, Hsieh MH, Tai CT, et al. Initiation of atrial fibrillation by ectopic beats originating from the pulmonary veins: electrophysiological characteristics, pharmacological responses, and effects of radiofrequency ablation. Circulation 1999; 100: 1879-86.
102. Katritsis D, Giazitzoglou E, Korovesis S, et al. Epicardial foci of atrial arrhythmias apparently originating in the left pulmonary veins. J Cardiovasc Electrophysiol 2002; 13: 319-23.
103. Katritsis D, Ioannidis JP, Giazitzoglou E, et al. Conduction delay within the coronary sinus in humans: implications for atrial arrhythmias. J Cardiovasc Electrophysiol 2002; 13: 859-62.
104. Blom NA, Gittenberger-de Groot AC, DeRuiter MC, et al. Development of the cardiac conduction tissue in human embryos using HNK-1 antigen expression: possible relevance for understanding of abnormal atrial automaticity. Circulation 1999; 99: 800-6.
105. Jongbloed MR, Schalij MJ, Poelmann RE, et al. Embryonic conduction tissue: a spatial correlation with adult arrhythmogenic areas. J Cardiovasc Electrophysiol 2004; 15: 349-55.
106. Perez-Lugones A, McMahon JT, Ratliff NB, et al. Evidence of specialized conduction cells in human pulmonary veins of patients with atrial fibrillation. J Cardiovasc Electrophysiol 2003; 14: 803-9.
107. Mommersteeg MT, Brown NA, Prall OW, et al. Pitx2c and Nkx2-5 are required for the formation and identity of the pulmonary myocardium. Circ Res 2007; 101: 902-9.
108. Pan NH, Tsao HM, Chang NC, et al. Aging dilates atrium and pulmonary veins: implications for the genesis of atrial fibrillation. Chest 2008; 133: 190-6.
109. Tsao HM, Wu MH, Huang BH, et al. Morphologic remodeling of pulmonary veins and left atrium after catheter ablation of atrial fibrillation: insight from long-term follow-up of three-dimensional magnetic resonance imaging. J Cardiovasc Electrophysiol 2005; 16: 7-12.
110. Benini K, Marini M, Del Greco M, et al. Role of multidetector computed tomography in the anatomical definition of the left atrium-pulmonary vein complex in patients with atrial fibrillation. Personal experience and pictorial assay. Radiol Med 2008; 113: 779-98.
111. Hassink RJ, Aretz HT, Ruskin J, et al. Morphology of atrial myocardium in human pulmonary veins: a postmortem analysis in patients with and without atrial fibrillation. J Am Coll Cardiol 2003; 42: 1108-14.
112. Ho SY, Cabrera JA, Tran VH, et al. Architecture of the pulmonary veins: relevance to radiofrequency ablation. Heart 2001; 86: 265-70.
113. Scherr D, Arbab-Zadeh A, Calkins H, et al. "Right posterior" pulmonary vein: an unexpected anatomic variant detected by multislice computed tomography before catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol 2009; 20: 568.
114. Wazni OM, Tsao HM, Chen SA, et al. Cardiovascular imaging in the management of atrial fibrillation. J Am Coll Cardiol 2006; 48: 2077-84.
115. Kato R, Lickfett L, Meininger G, et al. Pulmonary vein anatomy in patients undergoing catheter ablation of atrial fibrillation: lessons learned by use of magnetic resonance imaging. Circulation 2003; 107: 2004-10.
116. Luyckx VA, Bertram JF, Brenner BM, et al. Effect of fetal and child health on kidney development and long-term risk of hypertension and kidney disease. Lancet 2013; 382: 273-83.
117. Ellinor PT, Shin JT, Moore RK, et al. Locus for atrial fibrillation maps to chromosome 6q14-16. Circulation 2003; 107: 2880-3.
118. Volders PG, Zhu Q, Timmermans C, et al. Mapping a novel locus for familial atrial fibrillation on chromosome 10p11-q21. Heart Rhythm 2007; 4: 469-75.
119. Darbar D, Hardy A, Haines JL, et al. Prolonged signal-averaged Pwave duration as an intermediate phenotype for familial atrial fibrillation. J Am Coll Cardiol 2008; 51: 1083-9.
120. Yamashita T, Hayami N, Ajiki K, et al. Is ACE gene polymorphism associated with lone atrial fibrillation? Jpn Heart J 1997; 38: 637-41.
121. Tsai CT, Lai LP, Lin JL, et al. Renin-angiotensin system gene polymorphisms and atrial fibrillation. Circulation 2004; 109: 1640-6.
122. Watanabe H, Kaiser DW, Makino S, et al. ACE I/D polymorphism associated with abnormal atrial and atrioventricular conduction in lone atrial fibrillation and structural heart disease: implications for electrical remodeling. Heart Rhythm 2009; 6: 1327-32.
123. Ellinor PT, Lunetta KL, Albert CM, et al. Meta-analysis identifies six new susceptibility loci for atrial fibrillation. Nat Genet 2012; 44: 670-5.
124. Antzelevitch C, Pollevick GD, Cordeiro JM, et al. Loss-of-function mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden cardiac death. Circulation 2007; 115: 442-9.
125. Olesen MS, Holst AG, Jabbari J, et al. Genetic loci on chromosomes 4q25, 7p31, and 12p12 are associated with onset of lone atrial fibrillation before the age of 40 years. The Canadian journal of cardiology 2012; 28: 191-5.
126. Thibodeau IL, Xu J, Li Q, et al. Paradigm of genetic mosaicism and lone atrial fibrillation: physiological characterization of a connexin 43-deletion mutant identified from atrial tissue. Circulation 2010; 122: 236-44.
127. Gollob MH. Cardiac connexins as candidate genes for idiopathic atrial fibrillation. Curr Opin Cardiol 2006; 21: 155-8.
128. Gollob MH, Jones DL, Krahn AD, et al. Somatic mutations in the connexin 40 gene (GJA5) in atrial fibrillation. N Engl J Med 2006; 354: 2677-88.
129. Christophersen IE, Holmegard HN, Jabbari J, et al. Rare variants in GJA5 are associated with early-onset lone atrial fibrillation. The Canadian journal of cardiology 2013; 29: 111-6.
130. Shi HF, Yang JF, Wang Q, et al. Prevalence and spectrum of GJA5 mutations associated with lone atrial fibrillation. Mol Med Rep 2013; 7: 767-74.
131. Sun Y, Yang YQ, Gong XQ, et al. Novel germline GJA5/connexin40 mutations associated with lone atrial fibrillation impair gap junctional intercellular communication. Human mutation 2013; 34: 603-9.
132. Wirka RC, Gore S, Van Wagoner DR, et al. A common connexin-40 gene promoter variant affects connexin-40 expression in human atria and is associated with atrial fibrillation. Circ Arrhythm Electrophysiol 2011; 4: 87-93.
133. Chaldoupi SM, Loh P, Hauer RN, et al. The role of connexin40 in atrial fibrillation. Cardiovascular Res 2009; 84: 15-23.
134. Chaldoupi SM, Soedamah-Muthu SS, Regieli J, et al. Absence of connexin 40 gene polymorphism, as a marker of undetected atrial fibrillation in patients with unexplained cerebral ischemic events. Eur J Cardiovasc Prev Rehabil 2009; 16: 616-20.
135. Firouzi M, Ramanna H, Kok B, et al. Association of human connexin40 gene polymorphisms with atrial vulnerability as a risk factor for idiopathic atrial fibrillation. Circ Res 2004; 95: e29-33.
136. Hauer RN, Groenewegen WA, Firouzi M, et al. Cx40 polymorphism in human atrial fibrillation. Adv Cardiol 2006; 42: 284-91.
137. Juang JM, Chern YR, Tsai CT, et al. The association of human connexin 40 genetic polymorphisms with atrial fibrillation. Int J Cardiol 2007; 116: 107-12.
138. Yang YQ, Wang MY, Zhang XL, et al. GATA4 loss-of-function mutations in familial atrial fibrillation. Clin Chim Acta 2011; 412: 1825-30.
139. Wang J, Sun YM, Yang YQ. Mutation spectrum of the GATA4 gene in patients with idiopathic atrial fibrillation. Mol Biol Rep 2012; 39: 8127-35.
140. Jiang JQ, Shen FF, Fang WY, et al. Novel GATA4 mutations in lone atrial fibrillation. Int J Mol Med 2011; 28: 1025-32.
141. Schreieck J, Dostal S, von Beckerath N, et al. C825T polymorphism of the G-protein beta3 subunit gene and atrial fibrillation: association of the TT genotype with a reduced risk for atrial fibrillation. Am Heart J 2004; 148: 545-50.
142. Duhme N, Schweizer PA, Thomas D, et al. Altered HCN4 channel C-linker interaction is associated with familial tachycardiabradycardia syndrome and atrial fibrillation. Eur Heart J 2012.
143. Olson TM, Alekseev AE, Liu XK, et al. Kv1.5 channelopathy due to KCNA5 loss-of-function mutation causes human atrial fibrillation. Hum Mol Genet 2006; 15: 2185-91.
144. Yang T, Yang P, Roden DM, et al. Novel KCNA5 mutation implicates tyrosine kinase signaling in human atrial fibrillation. Heart Rhythm 2010; 7: 1246-52.
145. Yang Y, Li J, Lin X, et al. Novel KCNA5 loss-of-function mutations responsible for atrial fibrillation. J Hum Genet 2009; 54: 277-83.
146. Christophersen IE, Olesen MS, Liang B, et al. Genetic variation in KCNA5: impact on the atrial-specific potassium current IKur in patients with lone atrial fibrillation. Eur Heart J 2013; 34: 1517-25.
147. Olesen MS, Refsgaard L, Holst AG, et al. A novel KCND3 gain-offunction mutation associated with early-onset of persistent lone atrial fibrillation. Cardiovascular Res 2013; 98: 488-95.
148. Olesen MS, Bentzen BH, Nielsen JB, et al. Mutations in the potassium channel subunit KCNE1 are associated with early-onset familial atrial fibrillation. BMC Med Genet 2012; 13: 24.
149. Yao J, Ma YT, Xie X, et al. Association of KCNE1 genetic polymorphisms with atrial fibrillation in a Chinese Han population. Genet Test Mol Biomarkers 2012; 16: 1343-6.
150. Liang C, Li X, Xu Y, et al. KCNE1 rs1805127 Polymorphism Increases the Risk of Atrial Fibrillation: A Meta-Analysis of 10 Studies. PloS one 2013; 8: e68690.
151. Ehrlich JR, Zicha S, Coutu P, et al. Atrial fibrillation-associated minK38G/S polymorphism modulates delayed rectifier current and membrane localization. Cardiovascular Res 2005; 67: 520-8.
152. Fatini C, Sticchi E, Genuardi M, et al. Analysis of minK and eNOS genes as candidate loci for predisposition to non-valvular atrial fibrillation. Eur Heart J 2006; 27: 1712-8.
153. Lai LP, Su MJ, Yeh HM, et al. Association of the human minK gene 38G allele with atrial fibrillation: evidence of possible genetic control on the pathogenesis of atrial fibrillation. Am Heart J 2002; 144: 485-90.
154. Yang Y, Xia M, Jin Q, et al. Identification of a KCNE2 gain-offunction mutation in patients with familial atrial fibrillation. Am J Hum Genet 2004; 75: 899-905.
155. Lundby A, Ravn LS, Svendsen JH, et al. KCNE3 mutation V17M identified in a patient with lone atrial fibrillation. Cell Physiol Biochem 2008; 21: 47-54.
156. Zeng Z, Tan C, Teng S, et al. The single nucleotide polymorphisms of I(Ks) potassium channel genes and their association with atrial fibrillation in a Chinese population. Cardiology 2007; 108: 97-103.
157. Ravn LS, Aizawa Y, Pollevick GD. Gain-of-function in IKS secondary to a mutation in KCNE5 associated with atrial fibrillation. Heart Rhythm 2008; 5: 427-35.
158. Xia M, Jin Q, Bendahhou S, et al. A Kir2.1 gain-of-function mutation underlies familial atrial fibrillation. Biochem Biophys Res Commun 2005; 332: 1012-9.
159. Delaney JT, Muhammad R, Blair MA, et al. A KCNJ8 mutation associated with early repolarization and atrial fibrillation. Europace 2012; 14: 1428-32.
160. Ellinor PT, Lunetta KL, Glazer NL, et al. Common variants in KCNN3 are associated with lone atrial fibrillation. Nat Genet 2010; 42: 240-4.
161. Chang SH, Chang SN, Hwang JJ, et al. Significant association of rs13376333 in KCNN3 on chromosome 1q21 with atrial fibrillation in a Taiwanese population. Circulation journal : official journal of the Japanese Circulation Society 2012; 76: 184-8.
162. Olesen MS, Jabbari J, Holst AG, et al. Screening of KCNN3 in patients with early-onset lone atrial fibrillation. Europace 2011; 13: 963-7.
163. Chen YH, Xu SJ, Bendahhou S, et al. KCNQ1 gain-of-function mutation in familial atrial fibrillation. Science 2003; 299: 251-4.
164. Das S, Makino S, Melman YF, et al. Mutation in the S3 segment of KCNQ1 results in familial lone atrial fibrillation. Heart Rhythm 2009; 6: 1146-53.
165. Chu HM, Feng MJ, Li YG, et al. Polymorphisms but not mutations of the KCNQ1 gene are associated with lone atrial fibrillation in the Chinese Han population. ScientificWorldJournal 2013; 2013: 373454.
166. Abraham RL, Yang T, Blair M, et al. Augmented potassium current is a shared phenotype for two genetic defects associated with familial atrial fibrillation. Journal of molecular and cellular cardiology 2010; 48: 181-90.
167. Otway R, Vandenberg JI, Guo G, et al. Stretch-sensitive KCNQ1 mutation A link between genetic and environmental factors in the pathogenesis of atrial fibrillation? J Am Coll Cardiol 2007; 49: 578-86.
168. Fatkin D, MacRae C, Sasaki T, et al. Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease. N Engl J Med 1999; 341: 1715-24.
169. Sebillon P, Bouchier C, Bidot LD, et al. Expanding the phenotype of LMNA mutations in dilated cardiomyopathy and functional consequences of these mutations. J Med Genet 2003; 40: 560-7.
170. Xie WH, Chang C, Xu YJ, et al. Prevalence and spectrum of Nkx2.5 mutations associated with idiopathic atrial fibrillation. Clinics (Sao Paulo) 2013; 68.
171. Hodgson-Zingman DM, Karst ML, Zingman LV, et al. Atrial natriuretic peptide frameshift mutation in familial atrial fibrillation. N Engl J Med 2008; 359: 158-65.
172. Oberti C, Wang L, Li L, et al. Genome-wide linkage scan identifies a novel genetic locus on chromosome 5p13 for neonatal atrial fibrillation associated with sudden death and variable cardiomyopathy. Circulation 2004; 110: 3753-9.
173. Zhang X, Chen S, Yoo S, et al. Mutation in nuclear pore component NUP155 leads to atrial fibrillation and early sudden cardiac death. Cell 2008; 135: 1017-27.
174. Gudbjartsson DF, Arnar DO, Helgadottir A, et al. Variants conferring risk of atrial fibrillation on chromosome 4q25. Nature 2007; 448: 353-7.
175. Benjamin EJ, Rice KM, Arking DE, et al. Variants in ZFHX3 are associated with atrial fibrillation in individuals of European ancestry. Nat Genet 2009; 41: 879-81.
176. Kaab S, Darbar D, van Noord C, et al. Large scale replication and meta-analysis of variants on chromosome 4q25 associated with atrial fibrillation. Eur Heart J 2009; 30: 813-9.
177. Shi L, Li C, Wang C, et al. Assessment of association of rs2200733 on chromosome 4q25 with atrial fibrillation and ischemic stroke in a Chinese Han population. Hum Genet 2009; 126: 843-9.
178. Viviani Anselmi C, Novelli V, Roncarati R, et al. Association of rs2200733 at 4q25 with atrial flutter/fibrillation diseases in an Italian population. Heart 2008; 94: 1394-6.
179. Parvez B, Shoemaker MB, Muhammad R, et al. Common genetic polymorphism at 4q25 locus predicts atrial fibrillation recurrence after successful cardioversion. Heart Rhythm 2013; 10: 849-55.
180. Lubitz SA, Sinner MF, Lunetta KL, et al. Independent susceptibility markers for atrial fibrillation on chromosome 4q25. Circulation 2010; 122: 976-84.
181. Goodloe AH, Herron KJ, Olson TM. Uncovering an intermediate phenotype associated with rs2200733 at 4q25 in lone atrial fibrillation. Am J Cardiol 2011; 107: 1802-5.
182. Chelu MG, Sarma S, Sood S, et al. Calmodulin kinase II-mediated sarcoplasmic reticulum Ca2+ leak promotes atrial fibrillation in mice. J Clin Invest 2009; 119: 1940-51.
183. Watanabe H, Darbar D, Kaiser DW, et al. Mutations in sodium channel beta1-and beta2-subunits associated with atrial fibrillation. Circ Arrhythm Electrophysiol 2009; 2: 268-75.
184. Olesen MS, Jespersen T, Nielsen JB, et al. Mutations in sodium channel beta-subunit SCN3B are associated with early-onset lone atrial fibrillation. Cardiovascular Res 2011; 89: 786-93.
185. Olson TM, Michels VV, Ballew JD, et al. Sodium channel mutations and susceptibility to heart failure and atrial fibrillation. Jama 2005; 293: 447-54.
186. Ellinor PT, Nam EG, Shea MA, et al. Cardiac sodium channel mutation in atrial fibrillation. Heart Rhythm 2008; 5: 99-105.
187. Makiyama T, Akao M, Shizuta S, et al. A novel SCN5A gain-offunction mutation M1875T associated with familial atrial fibrillation. J Am Coll Cardiol 2008; 52: 1326-34.
188. Darbar D, Kannankeril PJ, Donahue BS, et al. Cardiac sodium channel (SCN5A) variants associated with atrial fibrillation. Circulation 2008; 117: 1927-35.
189. Olesen MS, Yuan L, Liang B, et al. High prevalence of long QT syndrome-associated SCN5A variants in patients with early-onset lone atrial fibrillation. Circ Cardiovasc Genet 2012; 5: 450-9.
190. Chen LY, Ballew JD, Herron KJ, et al. A common polymorphism in SCN5A is associated with lone atrial fibrillation. Clinical pharmacology and therapeutics 2007; 81: 35-41.
191. Nyberg MT, Stoevring B, Behr ER, et al. The variation of the sarcolipin gene (SLN) in atrial fibrillation, long QT syndrome and sudden arrhythmic death syndrome. Clin Chim Acta 2007; 375: 87-91.
192. Olson TM, Terzic A. Human K(ATP) channelopathies: diseases of metabolic homeostasis. Pflugers Arch 2010; 460: 295-306.
193. Zang X, Zhang S, Xia Y, et al. SNP rs3825214 in TBX5 is associated with lone atrial fibrillation in Chinese Han population. PloS one 2013; 8: e64966.
194. Li C, Wang F, Yang Y, et al. Significant association of SNP rs2106261 in the ZFHX3 gene with atrial fibrillation in a Chinese Han GeneID population. Hum Genet 2011; 129: 239-46.
195. Gudbjartsson DF, Holm H, Gretarsdottir S, et al. A sequence variant in ZFHX3 on 16q22 associates with atrial fibrillation and ischemic stroke. Nat Genet 2009; 41: 876-8.
196. Cosio FG, Aliot E, Botto GL, et al. Delayed rhythm control of atrial fibrillation may be a cause of failure to prevent recurrences: reasons for change to active antiarrhythmic treatment at the time of the first detected episode. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 2008; 10: 21-7.
197. Chen YJ, Chen SA, Chang MS, et al. Arrhythmogenic activity of cardiac muscle in pulmonary veins of the dog: implication for the genesis of atrial fibrillation. Cardiovascular Res 2000; 48: 265-73.
198. Khan R. Identifying and understanding the role of pulmonary vein activity in atrial fibrillation. Cardiovascular Res 2004; 64: 387-94.
199. Nathan H, Eliakim M. The junction between the left atrium and the pulmonary veins. An anatomic study of human hearts. Circulation 1966; 34: 412-22.
200. Saito T, Waki K, Becker AE. Left atrial myocardial extension onto pulmonary veins in humans: anatomic observations relevant for atrial arrhythmias. J Cardiovasc Electrophysiol 2000; 11: 888-94.
201. Tagawa M, Higuchi K, Chinushi M, et al. Myocardium extending from the left atrium onto the pulmonary veins: a comparison between subjects with and without atrial fibrillation. Pacing and clinical electrophysiology : PACE 2001; 24: 1459-63.
202. Zipes DP. Mechanisms of clinical arrhythmias. Pacing and clinical electrophysiology : PACE 2003; 26: 1778-92.
203. Cha TJ, Ehrlich JR, Zhang L, et al. Atrial ionic remodeling induced by atrial tachycardia in the presence of congestive heart failure. Circulation 2004; 110: 1520-6.
204. Honjo H, Boyett MR, Niwa R, et al. Pacing-induced spontaneous activity in myocardial sleeves of pulmonary veins after treatment with ryanodine. Circulation 2003; 107: 1937-43.
205. Maupoil V, Bronquard C, Freslon JL, et al. Ectopic activity in the rat pulmonary vein can arise from simultaneous activation of alpha1-and beta1-adrenoceptors. British journal of pharmacology 2007; 150: 899-905.
206. Bode F, Sachs F, Franz MR. Tarantula peptide inhibits atrial fibrillation. Nature 2001; 409: 35-6.
207. Patterson E, Jackman WM, Beckman KJ, et al. Spontaneous pulmonary vein firing in man: relationship to tachycardia-pause early afterdepolarizations and triggered arrhythmia in canine pulmonary veins in vitro. J Cardiovasc Electrophysiol 2007; 18: 1067-75.
208. Frustaci A, Chimenti C, Bellocci F, et al. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 1997; 96: 1180-4.
209. Weijs B, de Vos CB, Limantoro I, et al. The presence of an atrial electromechanical delay in idiopathic atrial fibrillation as determined by tissue Doppler imaging. International journal of cardiology 2012; 156: 121-2.
210. Ramanna H, Hauer RN, Wittkampf FH, et al. Identification of the substrate of atrial vulnerability in patients with idiopathic atrial fibrillation. Circulation 2000; 101: 995-1001.
211. Weijs B, de Vos CB, Tieleman RG, et al. The occurrence of cardiovascular disease during 5-year follow-up in patients with idiopathic atrial fibrillation. Europace 2013; 15: 18-23.
212. Katritsis DG, Toumpoulis IK, Giazitzoglou E, et al. Latent arterial hypertension in apparently lone atrial fibrillation. J Interv Card Electrophysiol 2005; 13: 203-7.
213. Van Gelder IC, Groenveld HF, Crijns HJ, et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med 2010; 362: 1363-73.
214. Carlsson J, Miketic S, Windeler J, et al. Randomized trial of ratecontrol versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol 2003; 41: 1690-6.
215. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation--Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet 2000; 356: 1789-94.
216. Opolski G, Torbicki A, Kosior DA, et al. Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study. Chest 2004; 126: 476-86.
217. Dobrev D, Nattel S. New antiarrhythmic drugs for treatment of atrial fibrillation. Lancet 2010; 375: 1212-23.
218. Fogari R, Mugellini A, Zoppi A, et al. Effect of Telmisartan and Ramipril on Atrial Fibrillation Recurrence and Severity in Hypertensive Patients With Metabolic Syndrome and Recurrent Symptomatic Paroxysmal and Persistent Atrial Fibrillation. J Cardiovasc Pharmacol Ther 2011; Epub ahead of print.
219. Lally JA, Gnall EM, Seltzer J, et al. Non-antiarrhythmic drugs in atrial fibrillation: a review of non-antiarrhythmic agents in prevention of atrial fibrillation. J Cardiovasc Electrophysiol 2007; 18: 1222-8.
220. Mancia G, Jakobsen A, Heroys J, et al. Cardiac and vascular protection: the potential of ONTARGET. Medscape journal of medicine 2008; 10 Suppl: S7.
221. Savelieva I, Kakouros N, Kourliouros A, et al. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part II: secondary prevention. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 2011; 13: 610-25.
222. Sicouri S, Cordeiro JM, Talarico M, et al. Antiarrhythmic effects of losartan and enalapril in canine pulmonary vein sleeve preparations. J Cardiovasc Electrophysiol 2011; 22: 698-705.
223. Smit MD, Van Gelder IC. Upstream therapy of atrial fibrillation. Expert review of cardiovascular therapy 2009; 7: 763-78.
224. Sinno H, Derakhchan K, Libersan D, et al. Atrial ischemia promotes atrial fibrillation in dogs. Circulation 2003; 107: 1930-6.
225. Skalidis EI, Hamilos MI, Karalis IK, et al. Isolated atrial microvascular dysfunction in patients with lone recurrent atrial fibrillation. J Am Coll Cardiol 2008; 51: 2053-7.
226. Skalidis EI, Zacharis EA, Tsetis DK, et al. Endothelial cell function during atrial fibrillation and after restoration of sinus rhythm. Am J Cardiol 2007; 99: 1258-62.
227. Alasady M, Abhayaratna WP, Leong DP, et al. Coronary artery disease affecting the atrial branches is an independent determinant of atrial fibrillation after myocardial infarction. Heart rhythm : the official journal of the Heart Rhythm Society 2011; 8: 955-60.
228. Krahn AD, Manfreda J, Tate RB, et al. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 1995; 98: 476-84.
229. Range FT, Schafers M, Acil T, et al. Impaired myocardial perfusion and perfusion reserve associated with increased coronary resistance in persistent idiopathic atrial fibrillation. Eur Heart J 2007; 28: 2223-30.
230. Olesen JB, Gislason GH, Torp-Pedersen C, et al. Atrial fibrillation and vascular disease--a bad combination. Clinical cardiology 2012; 35 Suppl 1: 15-20.
231. Olesen JB, Lip GY, Lane DA, et al. Vascular disease and stroke risk in atrial fibrillation: a nationwide cohort study. Am J Med 2012; 125: 826 e13-23.
232. Hwang HJ, Lee MY, Youn HJ, et al. Association between plaque thickness of the thoracic aorta and recurrence of atrial fibrillation after ablation. Korean Circ J 2011; 41: 177-83.
233. Hurle A, Sanchez-Quintana D, Ho SY, et al. Capillary supply to the sinus node in subjects with long-term atrial fibrillation. The Annals of thoracic surgery 2010; 89: 38-43.
234. Nucifora G, Schuijf JD, Tops LF, et al. Prevalence of coronary artery disease assessed by multislice computed tomography coronary angiography in patients with paroxysmal or persistent atrial fibrillation. Circulation Cardiovascular imaging 2009; 2: 100-6.
235. de Bono JP, Stoll VM, Joshi A, et al. Cavotricuspid isthmus dependent flutter is associated with an increased incidence of occult coronary artery disease. Europace 2010; 12: 1774-7.
236. Violi F, Lip GY, Basili S. Peripheral artery disease and atrial fibrillation: a potentially dangerous combination. Internal and emergency medicine 2011.
237. Weijs B, Pisters R, Haest RJ, et al. Patients originally diagnosed with idiopathic atrial fibrillation more often suffer from insidious coronary artery disease compared to healthy sinus rhythm controls. Heart Rhythm 2012; 9: 1923-9.
238. Feinberg WM, Blackshear JL, Laupacis A, et al. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med 1995; 155: 469-73.
239. Goto S, Bhatt DL, Rother J, et al. Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. Am Heart J 2008; 156: 855-63, 63 e2.
240. Zusman O, Amit G, Gilutz H, et al. The significance of new onset atrial fibrillation complicating acute myocardial infarction. Clinical research in cardiology : official journal of the German Cardiac Society 2012; 101: 17-22.
241. Jahangir A, Lee V, Friedman PA, et al. Long-term progression and outcomes with aging in patients with lone atrial fibrillation: a 30-year follow-up study. Circulation 2007; 115: 3050-6.
242. Rienstra M, Hagens VE, Van Veldhuisen DJ, et al. Clinical characteristics of persistent lone atrial fibrillation in the RACE study. Am J Cardiol 2004; 94: 1486-90.
243. Schoonderwoerd BA, Van Gelder IC, Crijns HJ. Left ventricular ischemia due to coronary stenosis as an unexpected treatable cause of paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol 1999; 10: 224-8.
244. Ezzati M, Lopez AD, Rodgers A, et al. Selected major risk factors and global and regional burden of disease. Lancet 2002; 360: 1347-60.
245. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-52.
246. Vasan RS, Larson MG, Leip EP, et al. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study. Lancet 2001; 358: 1682-6.
247. Rothwell PM, Howard SC, Dolan E, et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet 2010; 375: 895-905.
248. Thomas MC, Dublin S, Kaplan RC, et al. Blood pressure control and risk of incident atrial fibrillation. American J Hypertension 2008; 21: 1111-6.
249. Grundvold I, Skretteberg PT, Liestol K, et al. Upper normal blood pressures predict incident atrial fibrillation in healthy middle-aged men: a 35-year follow-up study. Hypertension 2012; 59: 198-204.
250. Darbar D, Motsinger AA, Ritchie MD, et al. Polymorphism modulates symptomatic response to antiarrhythmic drug therapy in patients with lone atrial fibrillation. Heart Rhythm 2007; 4: 743-9.
251. Ellinor PT, Low AF, Macrae CA. Reduced apelin levels in lone atrial fibrillation. Eur Heart J 2006; 27: 222-6.
252. Ellinor PT, Low AF, Patton KK, et al. Discordant atrial natriuretic peptide and brain natriuretic peptide levels in lone atrial fibrillation. J Am Coll Cardiol 2005; 45: 82-6.
253. Patton KK, Ellinor PT, Heckbert SR, et al. N-terminal pro-B-type natriuretic peptide is a major predictor of the development of atrial fibrillation: the Cardiovascular Health Study. Circulation 2009; 120: 1768-74.
254. Potpara TS, Stankovic GR, Beleslin BD, et al. A 12-year follow-up study of patients with newly-diagnosed lone atrial fibrillation: Implications of arrhythmia progression on prognosis: The Belgrade Atrial Fibrillation Study. Chest 2012; 141: 339-47.
255. Duprez DA. Role of the renin-angiotensin-aldosterone system in vascular remodeling and inflammation: a clinical review. J Hypertension 2006; 24: 983-91.
256. Duprez DA, Somasundaram PE, Sigurdsson G, et al. Relationship between C-reactive protein and arterial stiffness in an asymptomatic population. Journal of human hypertension 2005; 19: 515-9.
257. Pu Q, Neves MF, Virdis A, et al. Endothelin antagonism on aldosterone-induced oxidative stress and vascular remodeling. Hypertension 2003; 42: 49-55.
258. Guvenc TS, Ilhan E, Hasdemir H, et al. A novel explanation for the cause of atrial fibrillation seen in atherosclerotic coronary artery disease: "downstream inflammation" hypothesis. Med Hypotheses 2010; 74: 665-7.
259. Pellegrino PL, Brunetti ND, De Gennaro L, et al. Inflammatory activation in an unselected population of subjects with atrial fibrillation: links with structural heart disease, atrial remodeling and recent onset. Internal and emergency medicine 2013; 8: 123-8.
260. Gungor B, Ozcan KS, Erdinler I, et al. Elevated levels of RDW is associated with non-valvular atrial fibrillation. J Thromb Thrombolysis 2013.
261. Hatzinikolaou-Kotsakou E, Tziakas D, Hotidis A, et al. Relation of C-reactive protein to the first onset and the recurrence rate in lone atrial fibrillation. Am J Cardiol 2006; 97: 659-61.
262. Leftheriotis DI, Fountoulaki KT, Flevari PG, et al. The predictive value of inflammatory and oxidative markers following the successful cardioversion of persistent lone atrial fibrillation. Int J Cardiol 2009; 135: 361-9.
263. Li J, Solus J, Chen Q, et al. Role of inflammation and oxidative stress in atrial fibrillation. Heart Rhythm 2010; 7: 438-44.
264. Liuba I, Ahlmroth H, Jonasson L, et al. Source of inflammatory markers in patients with atrial fibrillation. Europace 2008.
265. Luan Y, Guo Y, Li S, et al. Interleukin-18 among atrial fibrillation patients in the absence of structural heart disease. Europace 2010; 12: 1713-8.
266. Marcus GM, Whooley MA, Glidden DV, et al. Interleukin-6 and atrial fibrillation in patients with coronary artery disease: data from the Heart and Soul Study. Am Heart J 2008; 155: 303-9.
267. Yao SY, Chu JM, Chen KP, et al. Inflammation in lone atrial fibrillation. Clinical cardiology 2009; 32: 94-8.
268. Smit MD, Maass AH, De Jong AM, et al. Role of inflammation in early atrial fibrillation recurrence. Europace 2012; 14: 810-7.
269. Toutouzas K, Drakopoulou M, Dilaveris P, et al. Inflammation in lone atrial fibrillation: new insights by coronary sinus thermography. Int J Cardiol 2009; 134: 345-50.
270. Gungor B, Ekmekci A, Arman A, et al. Assessment of Interleukin-1 Gene Cluster Polymorphisms in Lone Atrial Fibrillation: New Insight into the Role of Inflammation in Atrial Fibrillation. Pacing Clin Electrophysiol 2013.
271. Henningsen KM, Olesen MS, Pedersen M, et al. Single nucleotide polymorphisms in inflammatory genes and the risk of early onset of lone atrial fibrillation. Inflamm Res 2010; 59: 965-9.
272. Henningsen KM, Olesen MS, Ravn LS, et al. Inflammatory single nucleotide polymorphisms and the risk of atrial fibrillation: a case control study. Inflamm Res 2011; 60: 209-11.
273. Dobrev D. Is altered atrial microRNA-ome a critical contributor to the pathophysiology of atrial fibrillation? Basic research in cardiology 2012; 107: 284.
274. Ling TY, Wang XL, Chai Q, et al. Regulation of the SK3 channel by microRNA-499-Potential role in atrial fibrillation. Heart Rhythm 2013; 10: 1001-9.
275. Lu Y, Zhang Y, Wang N, et al. MicroRNA-328 contributes to adverse electrical remodeling in atrial fibrillation. Circulation 2010; 122: 2378-87.
276. Luo X, Pan Z, Shan H, et al. MicroRNA-26 governs profibrillatory inward-rectifier potassium current changes in atrial fibrillation. J Clin Invest 2013; 123: 1939-51.
277. Adam O, Lohfelm B, Thum T, et al. Role of miR-21 in the pathogenesis of atrial fibrosis. Basic research in cardiology 2012; 107: 278.
278. Liu Z, Zhou C, Liu Y, et al. The expression levels of plasma micoRNAs in atrial fibrillation patients. PloS one 2012; 7: e44906.
279. Adam O, Frost G, Custodis F, et al. Role of Rac1 GTPase activation in atrial fibrillation. J Am Coll Cardiol 2007; 50: 359-67.
280. Abo A, Pick E, Hall A, et al. Activation of the NADPH oxidase involves the small GTP-binding protein p21rac1. Nature 1991; 353: 668-70.
281. Tsai CT, Lai LP, Kuo KT, et al. Angiotensin II activates signal transducer and activators of transcription 3 via Rac1 in atrial myocytes and fibroblasts: implication for the therapeutic effect of statin in atrial structural remodeling. Circulation 2008; 117: 344-55.
282. Reil JC, Hohl M, Oberhofer M, et al. Cardiac Rac1 overexpression in mice creates a substrate for atrial arrhythmias characterized by structural remodelling. Cardiovascular Res 2010; 87: 485-93.
283. Borissoff JI, Spronk HM, ten Cate H. The hemostatic system as a modulator of atherosclerosis. N Engl J Med 2011; 364: 1746-60.
284. Borissoff JI, Heeneman S, Kilinc E, et al. Early atherosclerosis exhibits an enhanced procoagulant state. Circulation 2010; 122: 821-30.
285. Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited. Lancet 2009; 373: 155-66.
286. Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 2003; 23: 168-75.
287. Freestone B, Lip GY, Chong AY, et al. Circulating endothelial cells in atrial fibrillation with and without acute cardiovascular disease. Thromb Haemost 2005; 94: 702-6.
288. Guazzi M, Arena R. Endothelial dysfunction and pathophysiological correlates in atrial fibrillation. Heart 2009; 95: 102-6.
289. Krishnamoorthy S, Lim SH, Lip GY. Assessment of endothelial (dys)function in atrial fibrillation. Ann Med 2009; 41: 576-90.
290. de Azevedo CF, Hadlich MS, Bezerra SG, et al. Prognostic value of CT angiography in patients with inconclusive functional stress tests. JACC Cardiovascular imaging 2011; 4: 740-51.
291. Dedic A, Genders TS, Ferket BS, et al. Stable angina pectoris: head-to-head comparison of prognostic value of cardiac CT and exercise testing. Radiology 2011; 261: 428-36.
292. Achenbach S, Raggi P. Imaging of coronary atherosclerosis by computed tomography. Eur Heart J 2010; 31: 1442-8.
293. Achenbach S, Ropers U, Kuettner A, et al. Randomized comparison of 64-slice single-and dual-source computed tomography coronary angiography for the detection of coronary artery disease. JACC Cardiovascular imaging 2008; 1: 177-86.
294. Husmann L, Herzog BA, Gaemperli O, et al. Diagnostic accuracy of computed tomography coronary angiography and evaluation of stress-only single-photon emission computed tomography/computed tomography hybrid imaging: comparison of prospective electrocardiogram-triggering vs. retrospective gating. Eur Heart J 2009; 30: 600-7.
295. Maruyama T, Takada M, Hasuike T, et al. Radiation dose reduction and coronary assessability of prospective electrocardiogram-gated computed tomography coronary angiography: comparison with retrospective electrocardiogram-gated helical scan. J Am Coll Cardiol 2008; 52: 1450-5.
296. Kirchhof P, Breithardt G, Aliot E, et al. Personalized management of atrial fibrillation: Proceedings from the fourth Atrial Fibrillation competence NETwork/European Heart Rhythm Association consensus conference. Europace 2013.
297. Daccarett M, Badger TJ, Akoum N, et al. Association of left atrial fibrosis detected by delayed-enhancement magnetic resonance imaging and the risk of stroke in patients with atrial fibrillation. J Am Coll Cardiol 2011; 57: 831-8.
298. Mahnkopf C, Badger TJ, Burgon NS, et al. Evaluation of the left atrial substrate in patients with lone atrial fibrillation using delayedenhanced MRI: implications for disease progression and response to catheter ablation. Heart Rhythm 2010; 7: 1475-81.
299. Neilan TG, Shah RV, Abbasi SA, et al. The Incidence, Pattern, and Prognostic value of Left Ventricular Myocardial Scar by Late Gadolinium Enhancement in Patients with Atrial Fibrillation. J Am Coll Cardiol 2013.
300. De Vos CB, Weijs B, Crijns HJ, et al. Atrial tissue Doppler imaging for prediction of new-onset atrial fibrillation. Heart 2009; 95: 835-40.
301. Weijs B, de Vos CB, Tieleman RG, et al. Clinical and echocardiographic correlates of intra-atrial conduction delay. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 2011; 13: 1681-7.
302. de Vos CB, Crijns HJ, Tieleman RG. The fibrillating atrial myocardium visualized: an unexploited source of information. Heart rhythm : the official journal of the Heart Rhythm Society 2009; 6: 1247-8.
303. De Vos CB, Pison L, Pisters R, et al. Atrial fibrillatory wall motion and degree of atrial remodeling in patients with atrial fibrillation: a tissue velocity imaging study. J Cardiovasc Electrophysiol 2009; 20: 1374-81.
304. Duytschaever M, Heyse A, de Sutter J, et al. Transthoracic tissue Doppler imaging of the atria: a novel method to determine the atrial fibrillation cycle length. J Cardiovasc Electrophysiol 2006; 17: 1202-9.
305. Cuculich PS, Wang Y, Lindsay BD, et al. Noninvasive characterization of epicardial activation in humans with diverse atrial fibrillation patterns. Circulation 2010; 122: 1364-72.
306. Rodriguez-Manero M, Namdar M, Sarkozy A, et al. Prevalence, clinical characteristics and management of atrial fibrillation in patients with Brugada syndrome. Am J Cardiol 2013; 111: 362-7.
307. Francis J, Antzelevitch C. Atrial fibrillation and Brugada syndrome. J Am Coll Cardiol 2008; 51: 1149-53.
308. Pappone C, Radinovic A, Manguso F, et al. New-onset atrial fibrillation as first clinical manifestation of latent Brugada syndrome: prevalence and clinical significance. Eur Heart J 2009; 30: 2985-92.
309. Rodriguez-Manero M, Sarkozy A, Chierchia GB, et al. Ajmaline Test and ESC 2010 clinical practice guidelines on atrial fibrillation. Rev Esp Cardiol (Engl Ed) 2012; 65: 392-3; author reply 3.
310. Belhassen B. Continuous positive airway pressure after circumferential pulmonary vein isolation: the recipe for improving the success rate of ablation in patients with obstructive sleep apnea and atrial fibrillation? J Am Coll Cardiol 2013; 62: 306-7.
311. Fein AS, Shvilkin A, Shah D, et al. Treatment of obstructive sleep apnea reduces the risk of atrial fibrillation recurrence after catheter ablation. J Am Coll Cardiol 2013; 62: 300-5.
312. Linz D, Ukena C, Neuberger HR. Treatment of obstructive sleep apnoea improves metabolic conditions and prevents initiation of antiarrhythmic therapy in a patient with atrial fibrillation. Europace 2013.
313. Hijazi Z, Oldgren J, Siegbahn A, et al. Biomarkers in atrial fibrillation: a clinical review. Eur Heart J 2013; 34: 1475-80.
314. Healey JS, Connolly SJ, Gold MR, et al. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med 2012; 366: 120-9.
315. Potpara TS, Marinkovic JM, Polovina MM, et al. Gender-related differences in presentation, treatment and long-term outcome in patients with first-diagnosed atrial fibrillation and structurally normal heart: the Belgrade atrial fibrillation study. Int J Cardiol 2012; 161: 39-44.
316. Camm AJ, Lip GY, De Caterina R, et al 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33: 2719-47.
317. Kirchhof P, Curtis AB, Skanes AC, et al. Atrial fibrillation guidelines across the Atlantic: a comparison of the current recommendations of the European Society of Cardiology/European Heart Rhythm Association/European Association of Cardiothoracic Surgeons, the American College of Cardiology Foundation/American Heart Association/Heart Rhythm Society, and the Canadian Cardiovascular Society. Eur Heart J 2013; 34: 1471-4.
318. Achenbach S, Schmermund A, Erbel R, et al. [Detection of coronary calcifications by electron beam tomography and multislice spiral CT: clinical relevance]. Zeitschrift fur Kardiologie 2003; 92: 899-907.
319. Agatston AS, Janowitz WR, Hildner FJ, et al. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990; 15: 827-32.
320. Rumberger JA, Sheedy PF, Breen JF, et al. Electron beam computed tomographic coronary calcium score cutpoints and severity of associated angiographic lumen stenosis. J Am Coll Cardiol 1997; 29: 1542-8.
321. Budoff MJ, Gul KM. Expert review on coronary calcium. Vasc Health Risk Manag 2008; 4: 315-24.
322. Budoff MJ, McClelland RL, Nasir K, et al. Cardiovascular events with absent or minimal coronary calcification: the Multi-Ethnic Study of Atherosclerosis (MESA). Am Heart J 2009; 158: 554-61.
323. Budoff MJ, Shaw LJ, Liu ST, et al. Long-term prognosis associated with coronary calcification: observations from a registry of 25,253 patients. J Am Coll Cardiol 2007; 49: 1860-70.
324. Vliegenthart R, Hollander M, Breteler MM, et al. Stroke is associated with coronary calcification as detected by electron-beam CT: the Rotterdam Coronary Calcification Study. Stroke 2002; 33: 462-5.
325. Vliegenthart R, Oudkerk M, Song B, et al. Coronary calcification detected by electron-beam computed tomography and myocardial infarction. The Rotterdam Coronary Calcification Study. Eur Heart J 2002; 23: 1596-603.
326. Weijs B, Blaauw Y, Rennenberg RJ, et al. Patients using vitamin K antagonists show increased levels of coronary calcification: an observational study in low-risk atrial fibrillation patients. Eur Heart J 2011; 32: 2555-62.
327. Mahmoodi BK, Brouwer JL, Ten Kate MK, et al. A prospective cohort study on the absolute risks of venous thromboembolism and predictive value of screening asymptomatic relatives of patients with hereditary deficiencies of protein S, protein C or antithrombin. Journal of thrombosis and haemostasis : JTH 2010; 8: 1193-200.
328. Mahmoodi BK, Brouwer JL, Veeger NJ, et al. Hereditary deficiency of protein C or protein S confers increased risk of arterial thromboembolic events at a young age: results from a large family cohort study. Circulation 2008; 118: 1659-67.
329. Matsumoto K, Yano Y, Gabazza EC, et al. Inverse correlation between activated protein C generation and carotid atherosclerosis in Type 2 diabetic patients. Diabetic medicine : a journal of the British Diabetic Association 2007; 24: 1322-8.
330. Zorio E, Navarro S, Medina P, et al. Circulating activated protein C is reduced in young survivors of myocardial infarction and inversely correlates with the severity of coronary lesions. Journal of thrombosis and haemostasis : JTH 2006; 4: 1530-6.
331. Cranenburg EC, Schurgers LJ, Vermeer C. Vitamin K: the coagulation vitamin that became omnipotent. Thromb Haemost 2007; 98: 120-5.
332. Jono S, Ikari Y, Vermeer C, et al. Matrix Gla protein is associated with coronary artery calcification as assessed by electron-beam computed tomography. Thromb Haemost 2004; 91: 790-4.
333. Luo G, Ducy P, McKee MD, et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 1997; 386: 78-81.
334. Price PA, Faus SA, Williamson MK. Warfarin causes rapid calcification of the elastic lamellae in rat arteries and heart valves. Arterioscler Thromb Vasc Biol 1998; 18: 1400-7.
335. Schurgers LJ, Aebert H, Vermeer C, et al. Oral anticoagulant treatment: friend or foe in cardiovascular disease? Blood 2004; 104: 3231-2.
336. Rennenberg RJ, van Varik BJ, Schurgers LJ, et al. Chronic coumarin treatment is associated with increased extra-coronary arterial calcification in humans. Blood 2010; Epub ahead of print.
337. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-51.
338. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-92.
339. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-91.
340. Borissoff JI, Spronk HM, Heeneman S, et al. Is thrombin a key player in the 'coagulation-atherogenesis' maze? Cardiovascular Res 2009; 82: 392-403.
341. Piccini JP, Stevens SR, Chang Y, et al. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (An-Ticoagulation and Risk factors In Atrial fibrillation) study cohorts. Circulation 2013; 127: 224-32.
342. Savelieva I, Kakouros N, Kourliouros A, et al. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention. Europace 2011; 13: 308-28.
343. Belluzzi F, Sernesi L, Preti P, et al. Prevention of recurrent lone atrial fibrillation by the angiotensin-II converting enzyme inhibitor ramipril in normotensive patients. J Am Coll Cardiol 2009; 53: 24-9.
344. Madrid AH, Marin IM, Cervantes CE, et al. Prevention of recurrences in patients with lone atrial fibrillation. The dose-dependent effect of angiotensin II receptor blockers. Journal of the reninangiotensin-aldosterone system : JRAAS 2004; 5: 114-20.
345. Yang D, Yuan J, Liu G, et al. Angiotensin receptor blockers and statins could alleviate atrial fibrosis via regulating platelet-derived growth factor/Rac1/nuclear factor-kappa B Axis. Int J Med Sci 2013; 10: 812-24.
346. Adam O, Lavall D, Theobald K, et al. Rac1-induced connective tissue growth factor regulates connexin 43 and N-cadherin expression in atrial fibrillation. J Am Coll Cardiol 2010; 55: 469-80.
347. Burstein B, Nattel S. Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. J Am Coll Cardiol 2008; 51: 802-9.
348. Nattel S, Burstein B, Dobrev D. Atrial remodeling and atrial fibrillation: mechanisms and implications. Circ Arrhythm Electrophysiol 2008; 1: 62-73.
349. Verheule S, Sato T, Everett Tt, et al. Increased vulnerability to atrial fibrillation in transgenic mice with selective atrial fibrosis caused by overexpression of TGF-beta1. Circ Res 2004; 94: 1458-65.
350. Adam O, Laufs U. Rac1-mediated effects of HMG-CoA reductase inhibitors (statins) in cardiovascular disease. Antioxid Redox Signal 2013.
351. Siu CW, Lau CP, Tse HF. Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. Am J Cardiol 2003; 92: 1343-5.
352. Reilly SN, Jayaram R, Nahar K, et al. Atrial sources of reactive oxygen species vary with the duration and substrate of atrial fibrillation: implications for the antiarrhythmic effect of statins. Circulation 2011; 124: 1107-17.
353. Adam O, Neuberger HR, Bohm M, et al. Prevention of atrial fibrillation with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Circulation 2008; 118: 1285-93.
354. Girmatsion Z, Biliczki P, Bonauer A, et al. Changes in microRNA-1 expression and IK1 up-regulation in human atrial fibrillation. Heart Rhythm 2009; 6: 1802-9.
355. Alings M, Smit MD, Moes ML, et al. Routine versus aggressive upstream rhythm control for prevention of early atrial fibrillation in heart failure: background, aims and design of the RACE 3 study. Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation 2013; 21: 354-63.
356. Briet M, Schiffrin EL. Vascular actions of aldosterone. J Vasc Res 2013; 50: 89-99.
357. Mayyas F, Alzoubi KH, Van Wagoner DR. Impact of aldosterone antagonists on the substrate for atrial fibrillation: Aldosterone promotes oxidative stress and atrial structural/electrical remodeling. Int J Cardiol 2013.
358. Deftereos S, Giannopoulos G, Kossyvakis C, et al. Effectiveness of moxonidine to reduce atrial fibrillation burden in hypertensive patients. Am J Cardiol 2013; 112: 684-7.
359. Mayyas F, Niebauer M, Zurick A, et al. Association of left atrial endothelin-1 with atrial rhythm, size, and fibrosis in patients with structural heart disease. Circ Arrhythm Electrophysiol 2010; 3: 369-79.
360. Kaoukis A, Deftereos S, Raisakis K, et al. The role of endothelin system in cardiovascular disease and the potential therapeutic perspectives of its inhibition. Curr Top Med Chem 2013; 13: 95-114.
361. Schiffrin EL, Intengan HD, Thibault G, et al. Clinical significance of endothelin in cardiovascular disease. Curr Opin Cardiol 1997; 12: 354-67.
362. Linz D, Hohl M, Nickel A, et al. Effect of renal denervation on neurohumoral activation triggering atrial fibrillation in obstructive sleep apnea. Hypertension 2013; 62: 767-74.
363. Pokushalov E, Romanov A, Corbucci G, et al. A randomized comparison of pulmonary vein isolation with versus without concomitant renal artery denervation in patients with refractory symptomatic atrial fibrillation and resistant hypertension. J Am Coll Cardiol 2012; 60: 1163-70.
364. Steinberg JS, Pokushalov E, Mittal S. Renal denervation for arrhythmias: hope or hype? Curr Cardiol Rep 2013; 15: 392.
365. Brundel BJ, Henning RH, Ke L, et al. Heat shock protein upregulation protects against pacing-induced myolysis in HL-1 atrial myocytes and in human atrial fibrillation. J Mol Cellular Cardiol 2006; 41: 555-62.
366. Brundel BJ, Ke L, Dijkhuis AJ, et al. Heat shock proteins as molecular targets for intervention in atrial fibrillation. Cardiovascular Res 2008; 78: 422-8.
367. Hoogstra-Berends F, Meijering RA, Zhang D, et al. Heat shock protein-inducing compounds as therapeutics to restore proteostasis in atrial fibrillation. Trends Cardiovasc Med 2012; 22: 62-8.
368. Meijering RA, Zhang D, Hoogstra-Berends F, et al. Loss of proteostatic control as a substrate for atrial fibrillation: a novel target for upstream therapy by heat shock proteins. Front Physiol 2012; 3: 36.
369. Sakabe M, Shiroshita-Takeshita A, Maguy A, et al. Effects of a heat shock protein inducer on the atrial fibrillation substrate caused by acute atrial ischaemia. Cardiovascular Res 2008; 78: 63-70.
370. Bukowska A, Hammwohner M, Sixdorf A, et al. Dronedarone prevents microcirculatory abnormalities in the left ventricle during atrial tachypacing in pigs. Br J Pharmacol 2012; 166: 964-80.
371. Heijman J, Heusch G, Dobrev D. Pleiotropic effects of antiarrhythmic agents: dronedarone in the treatment of atrial fibrillation. Clin Med Insights Cardiol 2013; 7: 127-40.
372. Heusch G, Schulz R. Pleiotropic effects of dronedarone on ischemia/reperfusion injury in heart and brain. Cardiovascular Drugs Therapy/Sponsored Int Soc Cardiovascular Pharmacotherapy 2012; 26: 257-63.
373. Hohnloser SH, Crijns HJ, van Eickels M, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009; 360: 668-78.
374. Greenberg HM, Dwyer EM, Jr., Hochman JS, et al. Interaction of ischaemia and encainide/flecainide treatment: a proposed mechanism for the increased mortality in CAST I. Br Heart J 1995; 74: 631-5.
375. Cosedis Nielsen J, Johannessen A, Raatikainen P, et al. Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation. N Engl J Med 2012; 367: 1587-95.
376. Wazni OM, Marrouche NF, Martin DO, et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. Jama 2005; 293: 2634-40.
377. Teh AW, Kistler PM, Lee G, et al. Electroanatomic remodeling of the left atrium in paroxysmal and persistent atrial fibrillation patients without structural heart disease. J Cardiovasc Electrophysiol 2012; 23: 232-8.
378. Teh AW, Kistler PM, Lee G, et al. Long-term effects of catheter ablation for lone atrial fibrillation: progressive atrial electroanatomic substrate remodeling despite successful ablation. Heart Rhythm 2012; 9: 473-80.
379. Ouyang F, Tilz R, Chun J, et al. Long-term results of catheter ablation in paroxysmal atrial fibrillation: lessons from a 5-year followup. Circulation 2010; 122: 2368-77.
380. Tzou WS, Marchlinski FE, Zado ES, et al. Long-term outcome after successful catheter ablation of atrial fibrillation. Circ Arrhythm Electrophysiol 2010; 3: 237-42.
381. Weerasooriya R, Khairy P, Litalien J, et al. Catheter ablation for atrial fibrillation: are results maintained at 5 years of follow-up? J Am Coll Cardiol 2011; 57: 160-6.
382. Hemels ME, Gu YL, Tuinenburg AE, et al. Favorable long-term outcome of Maze surgery in patients with lone atrial fibrillation. The Annals of thoracic surgery 2006; 81: 1773-9.
383. Moten SC, Rodriguez E, Cook RC, et al. New ablation techniques for atrial fibrillation and the minimally invasive cryo-maze procedure in patients with lone atrial fibrillation. Heart, lung & circulation 2007; 16 Suppl 3: S88-93.
384. Pruitt JC, Lazzara RR, Dworkin GH, et al. Totally endoscopic ablation of lone atrial fibrillation: initial clinical experience. Annals Thoracic Surgery 2006; 81: 1325-30; discussion 30-1.
385. Rodriguez LM, Geller JC, Tse HF, et al. Acute results of transvenous cryoablation of supraventricular tachycardia (atrial fibrillation, atrial flutter, Wolff-Parkinson-White syndrome, atrioventricular nodal reentry tachycardia). J Cardiovasc Electrophysiol 2002; 13: 1082-9.
386. Sagbas E, Akpinar B, Sanisoglu I, et al. Video-assisted bilateral epicardial pulmonary vein isolation for the treatment of lone atrial fibrillation. Annl Thoracic Surgery 2007; 83: 1724-30.
387. Gelsomino S, La Meir M, Luca F, et al. Treatment of lone atrial fibrillation: a look at the past, a view of the present and a glance at the future. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery 2012; 41: 1284-94.
388. La Meir M, Gelsomino S, Lorusso R, et al. The hybrid approach for the surgical treatment of lone atrial fibrillation: one-year results employing a monopolar radiofrequency source. J Cardiothorac Surg 2012; 7: 71.
389. Pison L, La Meir M, van Opstal J, et al. Hybrid thoracoscopic surgical and transvenous catheter ablation of atrial fibrillation. J Am Coll Cardiol 2012; 60: 54-61.
390. Van Gelder IC, Haegeli LM, Brandes A, et al. Rationale and current perspective for early rhythm control therapy in atrial fibrillation. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 2011; 13: 1517-25.
391. Botto GL, Padeletti L, Santini M, et al. Presence and duration of atrial fibrillation detected by continuous monitoring: crucial implications for the risk of thromboembolic events. J Cardiovasc Electrophysiol 2009; 20: 241-8.
392. Kirchhof P, Breithardt G, Camm AJ, et al. Improving outcomes in patients with atrial fibrillation: Rationale and design of the Early treatment of Atrial fibrillation for Stroke prevention Trial. Am Heart J 2013; 166: 442-8.
393. Scardi S, Mazzone C, Pandullo C, et al. Lone atrial fibrillation: prognostic differences between paroxysmal and chronic forms after 10 years of follow-up. Am Heart J 1999; 137: 686-91.
394. Gajewski J, Singer RB. Mortality in an insured population with atrial fibrillation. Jama 1981; 245: 1540-4.
395. Kopecky SL, Gersh BJ, McGoon MD, et al. Lone atrial fibrillation in elderly persons: a marker for cardiovascular risk. Arch Intern Med 1999; 159: 1118-22.
396. Rostagno C, Bacci F, Martelli M, et al. Clinical course of lone atrial fibrillation since first symptomatic arrhythmic episode. Am J Cardiol 1995; 76: 837-9.
397. Crijns HJ, Van den Berg MP, Van Gelder IC, et al. Management of atrial fibrillation in the setting of heart failure. Eur Heart J 1997; 18 Suppl C: C45-9.
398. Fu R, Wu S, Wu P, et al. A study of blood soluble P-selectin, fibrinogen, and von Willebrand factor levels in idiopathic and lone atrial fibrillation. Europace 2011; 13: 31-6.
399. Akutsu Y, Kaneko K, Kodama Y, et al. Significance of cardiac sympathetic nervous system abnormality for predicting vascular events in patients with idiopathic paroxysmal atrial fibrillation. Eur J Nucl Med Mol Imaging 2010; 37: 742-9.
400. Potpara TS, Polovina MM, Licina MM, et al. Predictors and prognostic implications of incident heart failure following the first diagnosis of atrial fibrillation in patients with structurally normal hearts: the Belgrade Atrial Fibrillation Study. Eur J Heart Fail 2013; 15: 415-24.
401. Zoller B, Ohlsson H, Sundquist J, et al. Family history as a risk factor for recurrent hospitalization for lone atrial fibrillation: a nationwide family study in Sweden. BMC Cardiovasc Disord 2012; 12: 121.
402. Potpara TS, Polovina MM, Licina MM, et al. Reliable identification of "truly low" thromboembolic risk in patients initially diagnosed with "lone" atrial fibrillation: the Belgrade atrial fibrillation study. Circ Arrhythm Electrophysiol 2012; 5: 319-26.
403. Chambers PW. Lone atrial fibrillation: Pathologic or not? Med Hypotheses 2007; 68: 281-7.
404. Furberg CD, Psaty BM, Manolio TA, et al. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol 1994; 74: 236-41.
405. Levy S, Maarek M, Coumel P, et al. Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. The College of French Cardiologists. Circulation 1999; 99: 3028-35.
406. Wyse DG. Idiopathic atrial fibrillation: a rose by any other name? Europace 2012; 14: 151-2.